Ultragenyx Pharmaceutical (MEX:RARE) Cyclically Adjusted FCF per Share: MXN-236.04 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:RARE Ultragenyx Pharmaceutical Inc MEX:RARE
59 GF Score
Price MXN450.00
GF Value MXN794.20
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Ultragenyx Pharmaceutical Cyclically Adjusted FCF per Share?

Ultragenyx Pharmaceutical MEX:RARE 59 Cyclically Adjusted FCF per Share is MXN-236.04 as of Jun. 2026. GuruFocus rates MEX:RARE with a GF Score™ of 59/100 and a GF Value™ of MXN794.20 (Possible Value Trap). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Ultragenyx Pharmaceutical's adjusted free cash flow per share for the three months ended in Jun. 2026 was MXN-16.781. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is MXN-236.04 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -8.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Ultragenyx Pharmaceutical was -8.40% per year. The lowest was -8.40% per year. And the median was -8.40% per year.

As of today (2026-08-30), Ultragenyx Pharmaceutical's current stock price is MXN450.00. Ultragenyx Pharmaceutical's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was MXN-236.04. Ultragenyx Pharmaceutical's Cyclically Adjusted Price-to-FCF of today is .


Ultragenyx Pharmaceutical  (MEX:RARE) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Ultragenyx Pharmaceutical Cyclically Adjusted FCF per Share Related Terms


Ultragenyx Pharmaceutical Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Ultragenyx Pharmaceutical's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ultragenyx Pharmaceutical Cyclically Adjusted FCF per Share Chart

Ultragenyx Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -101.29 -93.72 -175.31 -333.66

Ultragenyx Pharmaceutical Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -212.33 -257.42 -333.66 -375.10 -236.04

MEX:RARE vs ATAI, QURE, KOD: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Ultragenyx Pharmaceutical's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ultragenyx Pharmaceutical Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ultragenyx Pharmaceutical's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Ultragenyx Pharmaceutical's Cyclically Adjusted Price-to-FCF falls into.


MEX:RARE
59GF Score
Ultragenyx Pharmaceutical Inc MEX:RARE
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ultragenyx Pharmaceutical Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ultragenyx Pharmaceutical's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-16.781/333.9520*333.9520
=-16.781

Current CPI (Jun. 2026) = 333.9520.

Ultragenyx Pharmaceutical Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -15.519 241.428 -21.466
201612 -24.434 241.432 -33.797
201703 -27.761 243.801 -38.026
201706 -21.000 244.955 -28.630
201709 -26.931 246.819 -36.438
201712 -37.655 246.524 -51.009
201803 -33.299 249.554 -44.561
201806 -30.549 251.989 -40.485
201809 -26.091 252.439 -34.516
201812 -22.067 251.233 -29.333
201903 -36.031 254.202 -47.335
201906 -31.493 256.143 -41.060
201909 -32.000 256.759 -41.621
201912 -27.248 256.974 -35.410
202003 -44.169 258.115 -57.146
202006 31.433 257.797 40.719
202009 -23.933 260.280 -30.707
202012 -25.952 260.474 -33.273
202103 -53.541 264.877 -67.503
202106 -25.152 271.696 -30.915
202109 -24.298 274.310 -29.581
202112 -21.056 278.802 -25.221
202203 -51.471 287.504 -59.786
202206 -31.124 296.311 -35.078
202209 -34.856 296.808 -39.218
202212 -32.601 296.797 -36.682
202303 -46.595 301.836 -51.553
202306 -32.064 305.109 -35.095
202309 -29.549 307.789 -32.061
202312 -17.999 306.746 -19.595
202403 -40.156 312.332 -42.936
202406 -17.239 314.175 -18.324
202409 -14.147 315.301 -14.984
202412 -17.454 315.605 -18.469
202503 -38.665 319.799 -40.376
202506 -21.410 322.561 -22.166
202509 -16.958 324.800 -17.436
202512 -18.173 324.054 -18.728
202603 -36.388 330.213 -36.800
202606 -16.781 333.952 -16.781

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of MXN-236.04 mean?
Ultragenyx Pharmaceutical (MEX:RARE) has a Cyclically Adjusted FCF per Share of MXN-236.04 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Ultragenyx Pharmaceutical and its competitors.
Is Ultragenyx Pharmaceutical's Cyclically Adjusted FCF per Share too high?
Ultragenyx Pharmaceutical's current Cyclically Adjusted FCF per Share is MXN-236.04. Overall, Ultragenyx Pharmaceutical has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ultragenyx Pharmaceutical's Cyclically Adjusted FCF per Share compare to ATAI and QURE?
Ultragenyx Pharmaceutical's Cyclically Adjusted FCF per Share of MXN-236.04 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Ultragenyx Pharmaceutical and its competitors. Ultragenyx Pharmaceutical's current Cyclically Adjusted FCF per Share is MXN-236.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ultragenyx Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Ultragenyx Pharmaceutical (MEX:RARE) is currently considered Possible Value Trap. The stock's GF Value™ is MXN794.20, compared to a current price of MXN450.00 — trading 43.3% below its estimated fair value. The current Cyclically Adjusted FCF per Share is MXN-236.04. Ultragenyx Pharmaceutical's overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Ultragenyx Pharmaceutical (MEX:RARE), the current Cyclically Adjusted FCF per Share is MXN-236.04 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ultragenyx Pharmaceutical (MEX:RARE) Overvalued in 2026?

Based on GuruFocus' analysis, Ultragenyx Pharmaceutical stock appears to be undervalued. The current stock price of MXN450.00 is trading 43.3% below its estimated GF Value™ of MXN794.20. GuruFocus considers Ultragenyx Pharmaceutical to be Possible Value Trap.

Key valuation signals for MEX:RARE:

  • Cyclically Adjusted FCF per Share: MXN-236.04
  • GF Value™: MXN794.20 vs. price of MXN450.00 (43.3% below fair value)
  • GF Score™: 59/100 with 5 warning signs

No single metric tells the full story. See the MEX:RARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ultragenyx Pharmaceutical Business Description

Address 60 Leveroni Court, Novato, CA, USA, 94949
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
59GF Score

Get the complete analysis for MEX:RARE

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN450.00
Price
MXN794.20
GF Value